"目录号: HY-13673A
GPCR/G Protein-
Goserelin (ICI 118630)乙酸盐是GnRH激动剂。
GNRH Receptor
相关产品
Degarelix-Leuprolide Acetate-Alarelin Acetate-Triptorelin-Nafarelin-Deslorelin-Relugolix-Abarelix-Cetrorelix Acetate-Elagolix-Gonadorelin acetate-Goserelin-Lecirelin-Buserelin Acetate-
生物活性
Description
Goserelin (ICI 118630) acetate is an injectable gonadotropin releasing hormone superagonist (GnRH agonist).IC50 value:Target: GnRH agonistGoserelin is used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty. It may also be used in the treatment of male-to-female transsexuals and is favoured above other anti-androgens in some countries, such as the UK. It is available as a 1-month depot and a long-acting 3-month depot. Goserelin stimulates the production of the sex hormones testosterone and estrogen in a non-pulsatile (non-physiological) manner.
Clinical Trial
NCT00532272
National Cancer Center, Korea
Metastatic Breast Cancer
October 2005
Phase 2
NCT00429403
M.D. Anderson Cancer Center
Breast Cancer
August 2006
Phase 3
NCT00303524
AstraZeneca
Breast Cancer
February 2006
Phase 2
NCT00322348
AstraZeneca
Advanced Breast Cancer
April 2006
Phase 2
NCT00439751
Ontario Clinical Oncology Group (OCOG)-AstraZeneca
Prostate Cancer
April 2007
Phase 3
NCT00888082
AstraZeneca
Breast Cancer-Ovarian Function
Phase 3
NCT02072512
Hospital Affiliated to Military Medical Science, Beijing
Metastatic Breast Cancer
January 2014
Phase 2
NCT00851461
Ramathibodi Hospital-AstraZeneca
Spinobulbar Muscular Atrophy-Kennedy's Disease
April 2008
Phase 4
NCT00827307
Zhejiang Cancer Hospital
Mammography-Estrogen-Lipemia-Endometrium-Ultrasonography
June 2008
NCT01242748
Ferring Pharmaceuticals
Prostate Cancer
October 2010
Phase 3
NCT01266213
Samsung Medical Center-Asan Medical Center-Seoul National University Hospital-Severance Hospital-Ulsan University Hospital-Kosin University Gospel Hospital-Korea University Guro Hospital-Korea University Anam Hospital
Metastatic Breast Cancer-Estrogen Receptor Positive Tumor-Breast Cancer Nos Premenopausal
December 2010
Phase 2
NCT00423475
UNICANCER
Prostate Cancer
October 2006
Phase 3
NCT00946920
Ferring Pharmaceuticals
Prostate Cancer
June 2009
Phase 3
NCT01252693
Spectrum Pharmaceuticals, Inc
Prostate Cancer
November 2010
Phase 2
NCT00196846
German Breast Group
Breast Cancer
March 2005
Phase 2
NCT00841113
Speciality European Pharma Limited
Prostate Cancer
January 1999
Phase 3
NCT01964170
Astellas Pharma Inc
Prostate Cancer
August 2013
Phase 3
NCT01776008
National Cancer Institute (NCI)
Estrogen Receptor Positive-HER2/Neu Negative-Recurrent Breast Carcinoma-Stage IIA Breast Cancer-Stage IIB Breast Cancer-Stage IIIA Breast Cancer-Stage IIIB Breast Cancer-Stage IIIC Breast Cancer
January 2013
Phase 2
NCT01738724
University of Sao Paulo
Uterine Leiomyoma
January 2013
Phase 4
NCT00654524
Zhejiang University
Endometriosis
March 2008
Phase 4
NCT00217659
Southwest Oncology Group-National Cancer Institute (NCI)
Breast Cancer
September 2005
Phase 2
NCT00010010
New York University School of Medicine-National Cancer Institute (NCI)
Breast Cancer
June 2000
Phase 2
NCT00884273
Ferring Pharmaceuticals
Prostate Cancer
August 2009
Phase 3
NCT00831233
Ferring Pharmaceuticals
Prostate Cancer
April 2009
Phase 3
NCT00012090
Memorial Sloan Kettering Cancer Center-National Cancer Institute (NCI)
Fallopian Tube Cancer-Ovarian Cancer-Primary Peritoneal Cavity Cancer
September 2000
Phase 2
NCT01240928
Vanderbilt-Ingram Cancer Center
Metastatic Breast Cancer
Phase 1
NCT00833248
Ferring Pharmaceuticals
Prostate Cancer
April 2009
Phase 3
NCT01368263
Washington University School of Medicine-National Cancer Institute (NCI)
Estrogen Receptor-positive Breast Cancer-HER2-negative Breast Cancer-Stage II Breast Cancer-Stage IIIA Breast Cancer-Stage IIIB Breast Cancer-Stage IIIC Breast Cancer
September 2011
Phase 2
NCT00068601
Southwest Oncology Group-National Cancer Institute (NCI)-Cancer and Leukemia Group B-Eastern Cooperative Oncology Group-International Breast Cancer Study Group
Breast Cancer-Infertility-Menopausal Symptoms
October 2003
Phase 3
NCT01163084
National Cancer Institute (NCI)
Prostate Adenocarcinoma-Stage IIA Prostate Cancer-Stage IIB Prostate Cancer
July 9, 2010
Phase 1-Phase 2
NCT00031850
Institute of Cancer Research, United Kingdom-National Cancer Institute (NCI)
Breast Cancer
March 2000
NCT00849082
European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
May 1987
Phase 3
NCT02586675
H. Lee Moffitt Cancer Center and Research Institute-Novartis
Breast Cancer-Breast Cancer - Female-Breast Cancer - Male
February 15, 2016
Phase 1
NCT00454571
National Cancer Institute (NCI)
Recurrent Prostate Cancer
June 2006
Phase 2
NCT00293696
University of Tampere
Prostate Cancer
October 2004
Phase 4
NCT02132390
Peking Union Medical College Hospital
Breast Cancer-Chemotherapy Induced Amenorrhea-Ovarian Function Suppression
May 2014
Phase 3
NCT00235937
AstraZeneca
Breast Cancer
December 2001
Phase 2
NCT00309478
Austrian Breast & Colorectal Cancer Study Group
Early-Stage Breast Cancer
December 1990
Phase 3
NCT01744366
Ferring Pharmaceuticals
Prostate Cancer
January 2013
Phase 3
NCT00937768
Mayo Clinic-National Cancer Institute (NCI)
Prostate Adenocarcinoma-Stage IIA Prostate Cancer-Stage IIB Prostate Cancer-Stage III Prostate Cancer-Stage IV Prostate Cancer
July 2009
Phase 2
NCT00186121
Stanford University-AstraZeneca
Breast Cancer
October 2000
NCT01394263
Endo Pharmaceuticals
Prostate Cancer-Adenocarcinoma of the Prostate
May 2000
Phase 3
NCT02333370
Novartis Pharmaceuticals-Novartis
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
February 4, 2015
Phase 1
NCT01120236
National Cancer Institute (NCI)
Prostate Adenocarcinoma-Recurrent Prostate Carcinoma-Stage IV Prostate Cancer
December 2010
Phase 2
NCT00605267
AstraZeneca
Breast Cancer
October 2007
Phase 3
NCT02483767
Peking Union Medical College Hospital
Breast Cancer
June 2015
Phase 3
NCT00255268
AstraZeneca
Metastatic Prostate Cancer
August 2004
Phase 4
NCT01013506
Vanderbilt-Ingram Cancer Center-National Cancer Institute (NCI)
Breast Cancer
August 2009
Phase 2
NCT00912548
Korean Breast Cancer Study Group
Breast Cancer